Do analysts rate CO or CYH?

Community Health Systems has a consensus price target of $2.96, suggesting a potential upside of 1.49%. Given Community Health Systems' stronger consensus rating and higher possible upside, analysts clearly believe Community Health Systems is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Community Health Systems 2 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.88

Do analysts recommend CO or AUNA?

Auna has a consensus price target of $6.97, suggesting a potential upside of 36.07%. Given Auna's stronger consensus rating and higher probable upside, analysts plainly believe Auna is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Auna 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40

Which has higher earnings & valuation, CO or AUNA?

Global Cord Blood has higher revenue and earnings than Auna. Global Cord Blood is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.49 Auna $1.23B 0.31 $27.39M $0.07 73.14

Do analysts recommend CO or VMD?

Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 57.29%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Viemed Healthcare is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Viemed Healthcare 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend CO or TACO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CO or TACO?

Global Cord Blood has higher revenue and earnings than Berto Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.49 Berto Acquisition N/A N/A N/A N/A N/A

Is CO or TACO more profitable?

Company Net Margins Return on Equity Return on Assets Global Cord Blood N/A N/A N/A Berto Acquisition N/A N/A N/A

Do analysts recommend BDSX or CO?

Biodesix currently has a consensus target price of $31.33, indicating a potential upside of 7.20%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Global Cord Blood (CO) Competitors

$0.95 0.00 (0.00%)

As of 09/24/2026

Compare

CO vs. CYH, AUNA, VMD, TACO, and BDSX

Should you buy Global Cord Blood stock or one of its competitors? Global Cord Blood's main competitors and comparable companies include Community Health Systems (CYH), Auna (AUNA), Viemed Healthcare (VMD), Berto Acquisition (TACO), and Biodesix (BDSX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Global Cord Blood compare to Community Health Systems?

Global Cord Blood (NYSE:CO) and Community Health Systems (NYSE:CYH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Community Health Systems has a consensus price target of $2.96, suggesting a potential upside of 1.49%. Given Community Health Systems' stronger consensus rating and higher possible upside, analysts clearly believe Community Health Systems is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Community Health Systems	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88

Global Cord Blood has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Community Health Systems has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

Community Health Systems has a net margin of 2.10% compared to Global Cord Blood's net margin of 0.00%. Global Cord Blood's return on equity of 0.00% beat Community Health Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Community Health Systems	2.10%	-6.66%	0.62%

Community Health Systems has higher revenue and earnings than Global Cord Blood. Global Cord Blood is trading at a lower price-to-earnings ratio than Community Health Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Community Health Systems	$12.49B	0.03	$509M	$1.85	1.58

In the previous week, Community Health Systems had 4 more articles in the media than Global Cord Blood. MarketBeat recorded 4 mentions for Community Health Systems and 0 mentions for Global Cord Blood. Community Health Systems' average media sentiment score of 0.25 beat Global Cord Blood's score of 0.00 indicating that Community Health Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Community Health Systems	Neutral

85.0% of Community Health Systems shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 11.1% of Community Health Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Community Health Systems beats Global Cord Blood on 14 of the 16 factors compared between the two stocks.

How does Global Cord Blood compare to Auna?

Global Cord Blood (NYSE:CO) and Auna (NYSE:AUNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Global Cord Blood has higher revenue and earnings than Auna. Global Cord Blood is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Auna	$1.23B	0.31	$27.39M	$0.07	73.14

Auna has a net margin of 0.44% compared to Global Cord Blood's net margin of 0.00%. Auna's return on equity of 12.88% beat Global Cord Blood's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Auna	0.44%	12.88%	3.24%

Global Cord Blood has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Auna has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

In the previous week, Auna had 3 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Auna and 0 mentions for Global Cord Blood. Auna's average media sentiment score of 0.73 beat Global Cord Blood's score of 0.00 indicating that Auna is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Auna	Positive

Auna has a consensus price target of $6.97, suggesting a potential upside of 36.07%. Given Auna's stronger consensus rating and higher probable upside, analysts plainly believe Auna is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Auna	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Auna beats Global Cord Blood on 12 of the 15 factors compared between the two stocks.

How does Global Cord Blood compare to Viemed Healthcare?

Global Cord Blood (NYSE:CO) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Global Cord Blood has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Viemed Healthcare	$270.28M	1.25	$14.93M	$0.36	24.73

Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 57.29%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Viemed Healthcare is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

74.2% of Viemed Healthcare shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 20.6% of Viemed Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Viemed Healthcare has a net margin of 4.81% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 10.16% beat Global Cord Blood's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Viemed Healthcare	4.81%	10.16%	7.22%

In the previous week, Viemed Healthcare had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 1 mentions for Viemed Healthcare and 0 mentions for Global Cord Blood. Viemed Healthcare's average media sentiment score of 1.82 beat Global Cord Blood's score of 0.00 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Viemed Healthcare	Very Positive

Summary

Viemed Healthcare beats Global Cord Blood on 13 of the 16 factors compared between the two stocks.

How does Global Cord Blood compare to Berto Acquisition?

Global Cord Blood (NYSE:CO) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Global Cord Blood has higher revenue and earnings than Berto Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Berto Acquisition	N/A	N/A	N/A	N/A	N/A

Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Berto Acquisition	N/A	N/A	N/A

In the previous week, Berto Acquisition had 4 more articles in the media than Global Cord Blood. MarketBeat recorded 4 mentions for Berto Acquisition and 0 mentions for Global Cord Blood. Berto Acquisition's average media sentiment score of 0.99 beat Global Cord Blood's score of 0.00 indicating that Berto Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Berto Acquisition	Positive

Summary

Berto Acquisition beats Global Cord Blood on 3 of the 5 factors compared between the two stocks.

How does Global Cord Blood compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Global Cord Blood (NYSE:CO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Global Cord Blood has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. Global Cord Blood's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Global Cord Blood	N/A	N/A	N/A

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biodesix has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Biodesix currently has a consensus target price of $31.33, indicating a potential upside of 7.20%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Global Cord Blood has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.48	-$35.26M	-$3.17	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49

In the previous week, Biodesix had 8 more articles in the media than Global Cord Blood. MarketBeat recorded 8 mentions for Biodesix and 0 mentions for Global Cord Blood. Biodesix's average media sentiment score of 0.17 beat Global Cord Blood's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company	Overall Sentiment
Biodesix	Neutral
Global Cord Blood	Neutral

Summary

Biodesix beats Global Cord Blood on 10 of the 17 factors compared between the two stocks.

Get Global Cord Blood News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CO vs. The Competition

Export

Metric	Global Cord Blood	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$115.60M	$9.78B	$7.26B	$22.88B
Dividend Yield	N/A	2.59%	2.52%	3.61%
P/E Ratio	1.49	35.03	274.72	28.01
Price / Sales	0.09	5.08	682.55	21.97
Price / Cash	4.19	122.11	77.80	38.70
Price / Book	0.15	5.24	10.47	4.66
Net Income	$79.04M	$315.70M	$3.49B	$1.07B
7 Day Performance	-0.01%	0.98%	-1.15%	-1.12%
1 Month Performance	N/A	0.90%	-4.42%	-5.24%
1 Year Performance	-34.41%	18.53%	16.70%	7.88%

Global Cord Blood Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CO Global Cord Blood	N/A	$0.95 flat	N/A	-34.4%	$115.60M	$1.24B	1.49	1,202
CYH Community Health Systems	1.5675 of 5 stars	$2.85 -2.6%	$2.95 +3.7%	-10.3%	$401.17M	$12.49B	1.54	57,000	News Coverage Analyst Forecast
AUNA Auna	4.2638 of 5 stars	$5.15 +0.2%	$6.97 +35.3%	-23.2%	$381.17M	$4.67B	73.58	15,254
VMD Viemed Healthcare	4.4661 of 5 stars	$9.00 +0.5%	$14.00 +55.6%	+30.1%	$342.30M	$301.61M	24.96	1,382	Positive News
TACO Berto Acquisition	1.4315 of 5 stars	$10.45 +0.0%	N/A	+0.6%	$340.96M	N/A	N/A	7,892	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CO) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Global Cord Blood (CO) Competitors

CO vs. CYH, AUNA, VMD, TACO, and BDSX

How does Global Cord Blood compare to Community Health Systems?

Summary

How does Global Cord Blood compare to Auna?

Summary

How does Global Cord Blood compare to Viemed Healthcare?

Summary

How does Global Cord Blood compare to Berto Acquisition?

Summary

How does Global Cord Blood compare to Biodesix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Global Cord Blood (CO) Competitors

CO vs. CYH, AUNA, VMD, TACO, and BDSX

How does Global Cord Blood compare to Community Health Systems?

Do analysts rate CO or CYH?

Which has more volatility and risk, CO or CYH?

Is CO or CYH more profitable?

Which has stronger earnings and valuation, CO or CYH?

Does the media prefer CO or CYH?

Do insiders & institutionals hold more shares of CO or CYH?

Summary

How does Global Cord Blood compare to Auna?

Which has higher earnings & valuation, CO or AUNA?

Is CO or AUNA more profitable?

Which has more volatility & risk, CO or AUNA?

Does the media prefer CO or AUNA?

Do analysts recommend CO or AUNA?

Summary

How does Global Cord Blood compare to Viemed Healthcare?

Which has more volatility and risk, CO or VMD?

Which has stronger valuation & earnings, CO or VMD?

Do analysts recommend CO or VMD?

Do institutionals and insiders believe in CO or VMD?

Is CO or VMD more profitable?

Does the media prefer CO or VMD?

Summary

How does Global Cord Blood compare to Berto Acquisition?

Do analysts recommend CO or TACO?

Which has stronger earnings and valuation, CO or TACO?

Which has more risk & volatility, CO or TACO?

Is CO or TACO more profitable?

Does the media refer more to CO or TACO?

Summary

How does Global Cord Blood compare to Biodesix?

Is BDSX or CO more profitable?

Do insiders & institutionals have more ownership in BDSX or CO?

Which has more risk and volatility, BDSX or CO?

Do analysts recommend BDSX or CO?

Which has better earnings & valuation, BDSX or CO?

Does the media refer more to BDSX or CO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools